Solitary bone plasmacytoma: Long-term clinical outcomes in a single center

• Published in: Current problems in cancer 2024-06, Vol.50, p.101095, Article 101095
• Main Authors: Gao, Shan, Wang, Yu-tong, Ma, Guang-yu, Lu, Min-qiu, Chu, Bin, Shi, Lei, Fang, Li-juan, Xiang, Qiu-qing, Ding, Yue-hua, Bao, Li
• Format: Article
• Language: English
• Subjects: Bone tumors; Chemotherapy; Multiple myeloma-free survival; Plasma cell dyscrasia; Radiotherapy
• ISSN: 0147-0272; 1535-6345; 1535-6345
• DOI: 10.1016/j.currproblcancer.2024.101095

A solitary plasmacytoma is classified into a solitary plasmacytoma of the bone (SBP) and a solitary extramedullary (soft tissue mass) plasmacytoma, based on the site of the lesion. Despite the high local control rate with radiotherapy, approximately half of patients’ conditions progress to multiple myeloma (MM) within 3–5 years after diagnosis, with SBP having a worse prognosis. We retrospectively assessed the treatment and outcomes of patients with SBP in a hospital in China from 2008 to 2021. Twenty-four patients treated over 13 years with SBP were enrolled in this retrospective study. The most common sites for SBP were the axial skeleton and femur. The M protein was detected in 11 patients (46 %), of which 8 (33 %) had light chains, 2 (8 %) had immunoglobulin G kappa and 1 (4 %) had immunoglobulin D kappa. Flow cytometry revealed that 5 patients (21 %) had minimal bone marrow involvement. The treatment included chemotherapy, surgery, and radiotherapy in 18 (75 %), 12 (50 %), and 9 (38 %) patients, respectively, of whom 13 (54 %) received combined treatment. Over a median follow-up period of 67.2 months, 9 patients (38 %) developed MM in a median time of 101.5 months. The 5- and 10-year progression-free survival rates were 67.3 % and 37.4 %, respectively. One patient died due to pneumonia without progression and the other died due to relapse. This study confirmed the high rate of progression of SBP to MM, indicating a need for adjunct chemotherapy for the management of SBP.